Estimates of overall survival and event-free survival for patients treated at the RP2D of CLAG-M/sorafenib. Estimates of (A,C) OS and (B,D) EFS for patients treated with CLAG-M/sorafenib for (A-B) the entire RP2D cohort and (C-D) the RP2D cohort stratified based on FLT3 mutation status. Wt, wild-type.